Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAL-413 (Orotecan) in Recurrent Pediatric Solid Tumors
NCT04337177Phase 1Active, not recruiting
- Sponsor
- Valent BioSciences LLC
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of orotecan in solid tumor, neuroblastoma, rhabdomyosarcoma (RMS) and 3 more (3 arms), sponsored by Valent BioSciences LLC. Primary endpoint: Recommended Phase II Dose at 17 months. Started Oct 2021; status: active, not recruiting.
02
Drugs
orotecan
03
Conditions
solid tumorneuroblastomarhabdomyosarcoma (RMS)Ewing sarcomahepatoblastoma
Beyond the preview
Go deeper on NCT04337177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04337177.